Biomarker ID | 483 |
PMID | 20632177 |
Year | 2010 |
Biomarker | MMP-2 |
Biomarker Basis | Concentration Based (ng/ml) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated and Hypermethylated (PCa: 684.65 ± 129.36; Normal: 609.63 ± 172.58) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Bladder cancer,Plasma membrane estrogen receptor signaling,Angiopoietin receptor Tie2-mediated signaling,LPA receptor mediated events,Alpha-M beta-2 integrin signaling |
Experiment | Prostate Cancer Vs No Tumor |
Type of Biomarker | Diagnostic |
Cohort | 114 men were chosen for the study out of which 79 had no tumor and 34 had Prostate Cancer. |
Senstivity | 24.1% [11–43.4] |
Specificity | 78.6% [95% CI: 66.8–87.1] |
AUC | 0.706 ± 0.08 |
Accuracy | NA |
Level Of Significance | p=0.038 |
Method Used | ELISA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | MMP2 |